Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases.

By P. Elliott, B. Andersson, E. Arbustini, Z. Bilińska, F. Cecchi, P. Charron, O. Dubourg, U. Kühl, B. Maisch, W. McKenna and 6 more. European Heart Journal, 2007

2,841 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/bc0754a8135175ad284024f06b204a674348bd98

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

Citations in the corpus

Universal Definition and Classification of Heart Failure. (2021, background): “Many attempts have been made for morphofunctional classifications of cardiomyopathies in the past.(25,26,28,102) In this statement, we do not provide recommendations for classifications of specific cardiomyopathies, because we feel those remain outside the scope of this document.”
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “varies, with spontaneous complete resolution (paradoxically most often seen with acute fulminant myocarditis)(158) to the development of DCM despite immunosuppressive therapy.(159) The role of immunosuppressive therapy is controversial.”
Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. (2016, background): “–8 In particular, it is recognized that many patients have a long preclinical phase characterized by few if any symptoms and minor cardiac abnormalities that fall outside current disease definitions.(1,2,5,9) – 12 It is also clear that distinct subtypes in fact share a common DCM phenotype.”
Guideline of transthyretin-related hereditary amyloidosis for clinicians (2013, background): “Cardiac amyloidosis is generally considered to be a cardiomyopathy with a hypertrophic phenotype and restrictive pathophysiology, although a true restrictive filling pattern is seen only in advanced stages [44].”
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “The role of immunosuppressive therapy is controversial (159).”
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the preventionof sudden cardiac death (2015, neutral): “1 Definitions, epidemiology and survival data DCM is defined as LV dilatation and systolic dysfunction in the absence of abnormal loading conditions or CAD sufficient to cause global systolic impairment.(348) Some genetic defects that cause DCM can also cause systolic dysfunction without LV dilatati”
Dilated Cardiomyopathy (2007, neutral): “One of the major challenges in nonischemic Dilated Cardiomyopathy (DCM) is the complex and heterogeneous etiology of the disease [1].”
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡ (2008, neutral): “This report was drafted by a Writing Group of the Task Force (see title page) appointed by the CPG of the ESC.”